Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Recommendation of “Hold” from Analysts

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have received a consensus rating of “Hold” from the twenty-two brokerages that are covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $114.15.

Several equities research analysts recently issued reports on ZBH shares. Raymond James cut their price objective on shares of Zimmer Biomet from $119.00 to $104.00 and set an “outperform” rating on the stock in a report on Tuesday. Royal Bank of Canada cut their price target on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating on the stock in a research note on Tuesday. JMP Securities lowered their price objective on Zimmer Biomet from $140.00 to $125.00 and set a “market outperform” rating for the company in a research note on Wednesday. Morgan Stanley cut their target price on Zimmer Biomet from $115.00 to $95.00 and set an “equal weight” rating on the stock in a research report on Tuesday. Finally, Wells Fargo & Company decreased their price target on shares of Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating for the company in a research report on Tuesday.

Zimmer Biomet Trading Up 0.1 %

Shares of ZBH opened at $95.22 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. Zimmer Biomet has a 12 month low of $89.92 and a 12 month high of $122.25. The stock has a market cap of $18.84 billion, a PE ratio of 21.40, a P/E/G ratio of 1.95 and a beta of 0.78. The stock’s 50-day moving average is $104.43 and its two-hundred day moving average is $106.11.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. During the same quarter in the prior year, the business earned $1.94 EPS. Zimmer Biomet’s quarterly revenue was up 1.1% compared to the same quarter last year. Equities analysts forecast that Zimmer Biomet will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend was Monday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is 21.24%.

Insider Buying and Selling

In other news, SVP Lori Winkler sold 1,443 shares of the business’s stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. The trade was a 14.13 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Nordea Investment Management AB boosted its position in shares of Zimmer Biomet by 3.9% during the fourth quarter. Nordea Investment Management AB now owns 16,333 shares of the medical equipment provider’s stock worth $1,732,000 after buying an additional 609 shares during the period. ORG Partners LLC grew its stake in shares of Zimmer Biomet by 14,497.5% in the fourth quarter. ORG Partners LLC now owns 5,839 shares of the medical equipment provider’s stock worth $617,000 after purchasing an additional 5,799 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in shares of Zimmer Biomet by 8.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,845 shares of the medical equipment provider’s stock worth $1,710,000 after purchasing an additional 1,173 shares in the last quarter. Czech National Bank raised its stake in shares of Zimmer Biomet by 4.0% during the fourth quarter. Czech National Bank now owns 43,164 shares of the medical equipment provider’s stock valued at $4,559,000 after purchasing an additional 1,678 shares in the last quarter. Finally, Brookstone Capital Management lifted its holdings in Zimmer Biomet by 34.3% in the fourth quarter. Brookstone Capital Management now owns 8,581 shares of the medical equipment provider’s stock worth $906,000 after purchasing an additional 2,193 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.